Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
In vivo characterization of the molecular mechanisms and chemotherapeutic potentials of platinum-acridine hybrid drugs
FY 2011-12
Summary
The development of chemotherapeutics is vital in fighting cancers, as multiple drugs are needed to treat one type of tumor to minimize the possibility of tumor resistance occurring within the patient. Developing anti-cancer drugs is especially important in the most resilient cancers, such as relapsed cancers or advanced cancers like advanced non-small cell lung cancer (NSCLC), for which there is a limited number of treatments available.
Cisplatin, a platinum-based drug, is amongst the most successful drugs in treating certain cancers. However, NSCLC is inherently resistant to cisplatin. Due to these reasons, platinum-acridine (Pt-Acr) hybrid drugs were created, and the prototypical agent, Pt-Acramtu(EN), kills NSCLC cells by inserting into their DNA, stopping DNA synthesis. However, we need to understand if newly developed Pt-Acr analogues work the same way in cells and if they stop tumor growth before using them clinically. Because Pt-Acramtu(EN) has a different MOA in inhibiting DNA synthesis than cisplatin, we hypothesize that Pt-Acr analogues can be used in combination with other chemotherapeutics to successfully treat NSCLC or as salvage therapies to overcome existing tumor resistance.
We are characterizing the MOAs of 5 Pt-Acr hybrid drugs in yeast by using a high-throughput growth assay developed by our lab. Yeast, the model organism for eukaryotes, is an extremely powerful tool in functional genomics, as over 1/3 of its disease-associated proteins share at least 40% sequence identity with humans, which sets the gold-standard for genome-wide studies. This assay determines the drugs' gene targets and their molecular pathways. We are using our assay to generate genome-wide drug profiles for 5 Pt-Acr drugs in 4 different species of yeast. Conservation of gene targets between species of yeasts would indicate the possibility of conservation with humans. Knowing the MOAs of Pt-Acr drugs will bring them one step closer to clinical trials and in fighting NSCLC.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
255007
Name
Li Si Yang
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
In vivo characterization of the molecular mechanisms and chemotherapeutic potentials of platinum-acridine hybrid drugs
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Chemogenomic Assays; Pharmaceutical Sciences
Abstract
The development of chemotherapeutics is vital in fighting cancers, as multiple drugs are needed to treat one type of tumor to minimize the possibility of tumor resistance occurring within the patient. Developing anti-cancer drugs is especially important in the most resilient cancers, such as relapsed cancers or advanced cancers like advanced non-small cell lung cancer (NSCLC), for which there is a limited number of treatments available.
Cisplatin, a platinum-based drug, is amongst the most successful drugs in treating certain cancers. However, NSCLC is inherently resistant to cisplatin. Due to these reasons, platinum-acridine (Pt-Acr) hybrid drugs were created, and the prototypical agent, Pt-Acramtu(EN), kills NSCLC cells by inserting into their DNA, stopping DNA synthesis. However, we need to understand if newly developed Pt-Acr analogues work the same way in cells and if they stop tumor growth before using them clinically. Because Pt-Acramtu(EN) has a different MOA in inhibiting DNA synthesis than cisplatin, we hypothesize that Pt-Acr analogues can be used in combination with other chemotherapeutics to successfully treat NSCLC or as salvage therapies to overcome existing tumor resistance.
We are characterizing the MOAs of 5 Pt-Acr hybrid drugs in yeast by using a high-throughput growth assay developed by our lab. Yeast, the model organism for eukaryotes, is an extremely powerful tool in functional genomics, as over 1/3 of its disease-associated proteins share at least 40% sequence identity with humans, which sets the gold-standard for genome-wide studies. This assay determines the drugs' gene targets and their molecular pathways. We are using our assay to generate genome-wide drug profiles for 5 Pt-Acr drugs in 4 different species of yeast. Conservation of gene targets between species of yeasts would indicate the possibility of conservation with humans. Knowing the MOAs of Pt-Acr drugs will bring them one step closer to clinical trials and in fighting NSCLC.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Si Yang
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~